nach oben

Erschienen in:

01.06.2012 | Original Article

Donor-specific HLA antibodies and graft function in children after renal transplantation

verfasst von: Jenni Miettinen, Juha Peräsaari, Jouni Lauronen, Erik Qvist, Helena Valta, Mikko Pakarinen, Jussi Merenmies, Hannu Jalanko

Erschienen in: Pediatric Nephrology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The presence of circulating donor-specific human leukocyte antigen antibodies (HLA-DSA) has been associated with chronic antibody-mediated rejection, leading to progressive graft dysfunction and poor graft survival. The aim of this study was to investigate the incidence and significance of HLA-DSA in paediatric renal transplantation (RTx) patients.

Methods

A total of 294 post-transplant serum samples from 123 RTx patients were retrospectively analysed for HLA antibodies. Positive samples were further tested for HLA-DSA by a Luminex Single Antigen bead assay. The antibody findings were correlated to measured glomerular filtration rate (GFR) and clinical outcome.

Results

HLA antibodies were detected in half of the routine samples (140/294) taken 1 month to 10 years after RTx, and 40% (62/140) of these were HLA-DSA. Overall, one-third (42/123) of the patients had HLA-DSA, which mostly (65%) reacted against class II antigens. Detection of HLA-DSA was not associated with poor GFR at the time of sampling, and no exceptional deterioration of GFR after the HLA-DSA detection was noted in individual patients regardless of the antibody level. The presence of HLA-DSA in the first 2 years posttransplantation was not associated with poorer graft function later on.

Conclusion

Detection of HLA antibodies is common in children after RTx, and this finding, as such, does not predict any deterioration of graft function.

Meier-Kriesche HU, Schold JD, Kaplan B (2004) Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 4:1289–1295PubMedCrossRef

Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ (2010) Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90:68–74PubMedCrossRef

Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349:2326–2333PubMedCrossRef

Akalin E, Pascual M (2006) Sensitization after kidney transplantation. Clin J Am Soc Nephrol 1:433–440PubMedCrossRef

Terasaki PI, Cai J (2008) Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 86:377–383PubMedCrossRef

Böhmig GA, Bartel G, Regele H, Wahrmann M (2009) Prospects and limitations of post-transplantation alloantibody detection in renal transplantation. Hum Immunol 70:640–644PubMedCrossRef

Jordan SC, Reinsmoen N, Peng A, Lai CH, Cao K, Villicana R, Toyoda M, Kahwaji J, Vo AA (2010) Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol 25:2035–2045PubMedCrossRef

Riethmüller S, Ferrari-Lacraz S, Müller MK, Raptis DA, Hadaya K, Rüsi B, Laube G, Schneiter G, Fehr T, Villard J (2010) Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 90:160–167PubMedCrossRef

Cai J, Terasaki PI (2008) Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol 20:602–606PubMedCrossRef

10.

Lachmann N, Terasaki PI, Budde K, Liefeldt L, Kahl A, Reinke P, Pratschke J, Rudolph B, Schmidt D, Salama A, Schönemann C (2009) Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 87:1505–1513PubMedCrossRef

11.

Hourmant M, Cesbron-Gautier A, Terasaki PI, Mizutani K, Moreau A, Meurette A, Dantal J, Giral M, Blancho G, Cantarovich D, Karam G, Follea G, Soulillou JP, Bignon JD (2005) Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 16:2804–2812PubMedCrossRef

12.

Claas FH (2010) Clinical relevance of circulating donor-specific HLA antibodies. Curr Opin Organ Transplant 15:462–466PubMedCrossRef

13.

Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL, Tsai A, Lei HY (2002) All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 74:1192–1194PubMedCrossRef

14.

Terasaki PI, Ozawa M, Castro R (2007) Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 7:408–415PubMedCrossRef

15.

Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD (2009) Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 70:584–588PubMedCrossRef

16.

Aubert V, Venetz JP, Pantaleo G, Pascual M (2009) Are all donor-specific antibodies detected by solid-phase assay before transplantation clinically relevant? Transplantation 87:1897–1898PubMedCrossRef

17.

Bartel G, Regele H, Wahrmann M, Huttary N, Exner M, Hörl WH, Böhmig GA (2008) Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 8:2652–2660PubMedCrossRef

18.

Süsal C, Ovens J, Mahmoud K, Döhler B, Scherer S, Ruhenstroth A, Tran TH, Heinoid A, Opelz G (2011) No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation 91:883–887PubMedCrossRef

19.

Girnita AL, Webber SA, Zeevi A (2006) Anti-HLA alloantibodies in pediatric solid organ transplantation. Pediatr Transplant 10:146–153PubMedCrossRef

20.

Roberti I, Vyas S, Pancoska C (2007) Donor-specific antibodies by flow single antigen beads in pediatric living donor kidney transplants: single center experience. Pediatr Transplant 11:901–905PubMedCrossRef

21.

Verghese PS, Smith JM, McDonald RA, Schwartz SM, Nelson KA, Warner PR (2010) Impaired graft survival in pediatric renal transplant recipients with donor-specific antibodies detected by solid-phase assays. Pediatr Transplant 14:730–734PubMedCrossRef

22.

Emonds MP, Herman J, Dendievel J, Waer M, Van Damme-Lombaerts R (2000) Evaluation of anti-human leukocyte antigen allo-immunization in pediatric cadaveric kidney transplantation. Pediatr Transplant 4:6–11PubMedCrossRef

23.

Valta H, Jalanko H, Holmberg C, Helenius I, Mäkitie O (2008) Impaired bone health in adolescents after liver transplantation. Am J Transplant 8:150–157PubMed

24.

Jodal L, Brochner-Mortensen J (2009) Reassessment of a classical single injection 51Cr-EDTA clearance method for determination of renal function in children and adults. Part I: Analytically correct relationship between total and one-pool clearance. Scand J Clin Lab Invest 69:305–313PubMedCrossRef

25.

Eng HS, Bennett G, Bardy P, Coghlan P, Russ GR, Coates PT (2009) Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum Immunol 70:595–599PubMedCrossRef

26.

Terasaki P, Lachmann N, Cai J (2006) Summary of the effect of de novo HLA antibodies on chronic kidney graft failure. Clin Transpl 455–462

27.

Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S (2009) Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 87:1681–1688PubMedCrossRef

28.

Gupta A, Sinnott P (2009) Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor. Hum Immunol 70:618–622PubMedCrossRef

29.

Fine RN, Malekzadeh MH, Pennisi AJ, Ettenger RB, Uittenbogaart CH, Korsch BM (1979) Renal transplantation in children. J Pediatr 95:244–248PubMedCrossRef

30.

Davenport A, Younie ME, Parsons JE, Klouda PT (1994) Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection. Nephrol Dial Transplant 9:1315–1319PubMed

31.

Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyran DB (2011) C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 91:342–347PubMedCrossRef

32.

Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, Rosenthal D, Reinhartz O, Tyan D (2011) Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 30:158–163PubMedCrossRef

Titel: Donor-specific HLA antibodies and graft function in children after renal transplantation
verfasst von: Jenni Miettinen
Juha Peräsaari
Jouni Lauronen
Erik Qvist
Helena Valta
Mikko Pakarinen
Jussi Merenmies
Hannu Jalanko
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Pediatric Nephrology / Ausgabe 6/2012
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-012-2101-4

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Donor-specific HLA antibodies and graft function in children after renal transplantation